Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Clinical trial NCT04419519 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT04419519

Sponsor

Memorial Sloan Kettering Cancer Center

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2020-05-13

Primary completion

2027-05-01

Enrollment

81

View on ClinicalTrials.gov